Holen Sie sich die Stockscreener-App
38.34
6.10%
-2.49
Handel nachbörslich:
38.62
0.28
+0.73%
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics IncorporatedCORT - PR Newswire
CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT) - GlobeNewswire
Options Exercise: Hazel Hunt At Corcept Therapeutics Realizes $5.53M - Benzinga
CORCEPT THERAPEUTICS Investors Are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law Violations - NewMediaWire
CORCEPT THERAPEUTICS INVESTIGATION ALERT: Corcept Therapeutics Faces Potential Securities Law ViolationsContact Kaplan Fox & Kilsheimer LLP - NewMediaWire
Corcept Therapeutics Faces Potential Securities Law ViolationsContact Kaplan Fox & Kilsheimer LLP - FinancialContent
CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT) INVESTIGATION ALERT: Bernstein Liebhard is ... - Bluefield Daily Telegraph
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm - GlobeNewswire Inc.
CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm - PR Newswire
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm - PR Newswire
CORT shares plummet on FDA’s drug rejection letter reveal — here’s what retail has to say - MSN
CORT SECURITIES INVESTIGATION: Kaplan Fox is Investigating Possible Securities Violations Against Corcept Therapeutics, Inc. (CORT) - The Globe and Mail
CORT SECURITIES INVESTIGATION: Kaplan Fox is Investigating Possib - The National Law Review
Kaplan Fox is Investigating Possible Securities Violations Against Corcept Therapeutics, Inc. (CORT) - FinancialContent
CORCEPT THERAPEUTICS Is Being Investigated for Potential Securities Law ViolationsContact Kaplan Fox & Kilsheimer LLP - NewMediaWire
FinancialContentCORCEPT THERAPEUTICS Is Being Investigated for Potential Securities Law ViolationsContact Kaplan Fox & Kilsheimer LLP - FinancialContent
Insider Sell: William Guyer Sells 20,000 Shares of Corcept Thera - GuruFocus
Insider Sell: William Guyer Sells 20,000 Shares of Corcept Therapeutics Inc (CORT) - GuruFocus
CORCEPT THERAPEUTICS SECURITIES INVESTIGATION: Kaplan Fox & Kilsheimer LLP is Investigating Corcept Therapeutics, Inc. (CORT) for Possible Securities Law Violations - The Globe and Mail
Despite lower earnings than three years ago, Corcept Therapeutics (NASDAQ:CORT) investors are up 71% since then - Yahoo Finance
CORT Investors Have Opportunity to Join Corcept Therapeutics Inc - GuruFocus
Corcept Therapeutics Incorporated (NASDAQ:CORT) Given Average Rating of "Hold" by Brokerages - MarketBeat
CORCEPT INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Lost Money on Corcept Therapeutics Incorporated (CORT)? Possible FraudContact Levi & Korsinsky Today - marketscreener.com
Securities Fraud Investigation Into Corcept Therapeutics Incorporated (CORT) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - The AI Journal
Published on: 2026-02-04 10:56:05 - baoquankhu1.vn
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - marketscreener.com
Securities Fraud Investigation Into Corcept Therapeutics Incorporated (CORT) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - The AI Journal
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Corcept ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Corcept Therapeutics Incorporated – CORT - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nutanix, Inc. - GlobeNewswire Inc.
Brown Capital Management LLC Makes New $19.95 Million Investment in Corcept Therapeutics Incorporated $CORT - MarketBeat
CORT FRAUD INVESTIGATION: Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (CORT) to Potential Securities Violations - NewMediaWire
FDA Warned Corcept of ‘Significant Review Issues’ for Rejected Drug in Early Meetings - BioSpace
DJS Law Group Investigates Corcept Securities Violations - intellectia.ai
Rosen Law Firm Investigates Securities Claims for Corcept Shareholders - intellectia.ai
Hagens Berman Investigating Corcept Therapeutics (CORT): Shares F - The National Law Review
Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Possible Securities Law Violations - NewMediaWire
Corcept Therapeutics Faces FDA Warning Over Drug Efficacy Claims - intellectia.ai
Hagens Berman Investigating Corcept Therapeutics (CORT): Shares Fall After Report That FDA Warned Against Relacorilant Drug Application Filing - The AI Journal
Corcept Therapeutics (CORT) Shares Drop After FDA Feedback - GuruFocus
Berman Tabacco Announces Investigation of Corcept - GlobeNewswire
Corcept submitted lead asset for approval despite FDA flagging risk of 'significant review issues' - Fierce Biotech
CORT Shares Plummet On FDA’s Drug Rejection Letter Reveal — Here’s What Retail Has To Say - Stocktwits
CORT Sees Increased Call Options Activity - GuruFocus
Rosen Law Firm Encourages Corcept Therapeutics Incorporated Investors to Inquire About Securities Class Action Investigation – CORT - Business Wire
Commit To Purchase Corcept Therapeutics At $25, Earn 18.7% Annualized Using Options - Nasdaq
Corcept shares tumble after FDA letter reveals warnings before drug rejection - Yahoo! Finance Canada
Corcept Therapeutics Investigated for Securities Fraud Following Report of FDA Warnings; Shareholders Should Contact Block & Leviton To Recover Losses - GlobeNewswire
Corcept Therapeutics (CORT) Stock Falls After FDA Rejects Drug A - GuruFocus
Corcept stock down as FDA revises CRL (CORT:NASDAQ) - Seeking Alpha
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):